Premium Company Profile Novavax
Premium Company Profile Novavax - New Research Report on Companies and Markets
© companiesandmarkets.com
15.11.2008 00:14:01 www.companiesandmarkets.com adds new report - Premium Company Profile Novavax
(live-PR.com) - www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
Novavax is a biopharmaceutical company focused on developing vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential as well as vaccines that protect against seasonal influenza. These vaccines leverage the company´s virus-like particle (VLP) platform technology, Novasome adjuvants and unique production technology.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis,
5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Novavax is focused on creating vaccines for a range of infectious diseases. The company´s Estrasorb is the first topical emulsion for estrogen therapy approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause. The company also markets Gynodiol used for estrogen replacement therapy.
The company´s total revenues declined at a CAGR of 25% during 2002-2006, from $15 million to $5 million. The major reason for revenue decline was the decreasing product sales. Product sales of the company decreased at a CAGR of 34% during 2002-2006, from $13 million to $3 million.
The company´s total revenues would increase at a CAGR of 12% during 2006-2010 from $5 million to $8 million. The company´s biggest contributor to revenue growth out to 2010 will be revenues from contract research and development.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
Introduction
Novavax is a biopharmaceutical company focused on developing vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential as well as vaccines that protect against seasonal influenza. These vaccines leverage the company´s virus-like particle (VLP) platform technology, Novasome adjuvants and unique production technology.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis,
|
|
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Novavax is focused on creating vaccines for a range of infectious diseases. The company´s Estrasorb is the first topical emulsion for estrogen therapy approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause. The company also markets Gynodiol used for estrogen replacement therapy.
The company´s total revenues declined at a CAGR of 25% during 2002-2006, from $15 million to $5 million. The major reason for revenue decline was the decreasing product sales. Product sales of the company decreased at a CAGR of 34% during 2002-2006, from $13 million to $3 million.
The company´s total revenues would increase at a CAGR of 12% during 2006-2010 from $5 million to $8 million. The company´s biggest contributor to revenue growth out to 2010 will be revenues from contract research and development.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
| Author: |
